# US 2006/0040278 A1 · Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0040278 A1
- Document ID: US20060040278A1
- Status: Published application
- Kind: A1
- Application number: 11/050,857
- Filed: 2005-01-27
- Published: 2006-02-23
- Earliest claimed: 2004-01-27
- Inventors: Gad Cojocaru; Sarah Pollock; Zurit Levine; Alexander Diber; Guy Kol; Amir Toporik; Rotem Sorek; Dvir Dahary; Michal Ayalon-Soffer; Pinchas Akiva; Amit Novik; Yossi Cohen; Osnat Sella-Tavor; Shira Walach; Shirley Sameah-Greenwald; Ronen Shemesh; Maxim Shklar
- Web page: https://patentgrep.com/patent/US20060040278A1

## CPC

- G01N 33/57545: of the ovaries
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states.

## Claims

### Claim 1

An isolated polynucleotide comprising a polynucleotide having a sequence of R11723_PEA—1_T5 (SEQ ID NO. 114).

### Claim 2 (depends on 1)

The isolated polynucleotide of claim 1, comprising a node having a sequence of: R11723_PEA—1_node—13 (SEQ ID NO. 116).

### Claim 3

An isolated polypeptide comprising a polypeptide having a sequence of: R11723_PEA—1_P13 (SEQ ID NO. 145).

### Claim 4 (depends on 3)

The isolated polypeptide of claim 3, comprising a chimeric polypeptide encoding for R11723_PEA—1_P13 (SEQ ID NO. 145), comprising a first amino acid sequence being at least 95% homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEVMEQSA corresponding to amino acids 1-63 of Q96AC2 (SEQ ID NO. 969), which also corresponds to amino acids 1-63 of R11723_PEA—1_P13 (SEQ ID NO. 145), and a second amino acid sequence being at least about 95% homologous to a polypeptide having the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO: 1130) corresponding to amino acids 64-84 of R11723_PEA—1_P13 (SEQ ID NO. 145), wherein said first and second amino acid sequences are contiguous and in a sequential order.

### Claim 5 (depends on 4)

The isolated polypeptide of claim 4, comprising a tail of R11723_PEA—1_P13 (SEQ ID NO. 145), comprising a polypeptide being at least about 95% homologous to the sequence DTKRTNTLLFEMRHFAKQLTT (SEQ ID NO: 1130) in R11723_PEA—1_P13 (SEQ ID NO. 145).

### Claim 6 (depends on 1)

The isolated polynucleotide of claim 1, comprising an amplicon according to SEQ ID NO: 975.

### Claim 7 (depends on 6)

A primer pair, comprising a pair of isolated oligonucleotides capable of amplifying said amplicon of claim 6.

### Claim 8 (depends on 7)

The primer pair of claim 7, comprising a pair of isolated oligonucleotides: SEQ NOs 973 and 974.

### Claim 9 (depends on 3)

An antibody capable of specifically binding to an epitope of an amino acid sequence of claim 3.

### Claim 10 (depends on 4, 9)

The antibody of claim 9, wherein said amino acid sequence comprises said tail of claim 4.

### Claim 11 (depends on 9)

The antibody of claim 9, wherein said antibody is capable of differentiating between a splice variant having said epitope and a corresponding known protein PSEC.

### Claim 12 (depends on 1)

A kit for detecting ovarian cancer, comprising a kit detecting overexpression of a splice variant according to claim 1.

### Claim 13 (depends on 12)

The kit of claim 12, wherein said kit comprises a NAT-based technology.

### Claim 14 (depends on 1, 12)

The kit of claim 12, wherein said kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence according to claim 1.

### Claim 15 (depends on 1, 12)

The kit of claim 12, wherein said kit further comprises at least one oligonucleotide capable of selectively hybridizing to a nucleic acid sequence according to claim 1.

### Claim 16 (depends on 3, 9)

A kit for detecting ovarian cancer, comprising a kit detecting overexpression of a splice variant according to claim 3, said kit comprising an antibody according claim 9.

### Claim 17 (depends on 16)

The kit of claim 16, wherein said kit further comprises at least one reagent for performing an ELISA or a Western blot.

### Claim 18 (depends on 1)

A method for detecting ovarian cancer, comprising detecting overexpression of a splice variant according to claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein said detecting overexpression is performed with a NAT-based technology.

### Claim 20 (depends on 3)

A method for detecting ovarian cancer, comprising detecting overexpression of a splice variant according to claim 3, wherein said detecting overexpression is performed with an immunoassay.

### Claim 21 (depends on 9, 20)

The method of claim 20, wherein said immunoassay comprises an antibody according to claim 9.

### Claim 22 (depends on 1, 3)

A biomarker capable of detecting ovarian cancer, comprising a nucleic acid sequence according to claim 1 or a fragment thereof, or an amino acid sequence according to claim 3 or a fragment thereof.

### Claim 23 (depends on 22)

A method for screening for ovarian cancer, comprising detecting ovarian cancer cells with a biomarker according to claim 22.

### Claim 24 (depends on 22)

A method for diagnosing ovarian cancer, comprising detecting ovarian cancer cells with a biomarker according to claim 22.

### Claim 25 (depends on 22)

A method for monitoring disease progression and/or treatment efficacy and/or relapse of ovarian cancer, comprising detecting ovarian cancer cells with a biomarker according to claim 22.

### Claim 26 (depends on 22)

A method of selecting a therapy for ovarian cancer, comprising detecting ovarian cancer cells with a biomarker according to claim 22 and selecting a therapy according to said detection.
